GLP-1 & compounded medication availability in Oklahoma (2026)
Oklahoma keeps it procedural: out-of-state pharmacies register with the state, keep a clean inspection on file, and name an Oklahoma-licensed pharmacist-in-charge, and that is most of what there is to know. Below: all ten OrderlyMeds product lines and whether each one ships to Oklahoma addresses, followed by the state’s actual requirements with the primary documents cited.
What ships to Oklahoma: all ten lines
| Product line | Available in Oklahoma? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Filled by pharmacies holding Oklahoma’s non-resident credential, per the cited rule below. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | National flat pricing, dose for dose. |
| NAD+ | Yes | 8–10 business days | Shipped by licensed partner pharmacies. |
| Sermorelin | Yes | 8–10 business days | Part of the longevity family; identical ordering flow. |
| Glutathione | No | N/A | Not offered by OrderlyMeds at this time. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; two federal facts below come with it. |
| TB-500 | Yes | 8–10 business days | Compounded injectable. Federal record in its section below. |
| KPV | No | N/A | Not carried anywhere, since the formulary is injectable-form only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal status stated below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its federal entry below stands alone. |
Every “No” above is published on purpose, because an honest matrix is the point of this page. Oklahoma facts were last reviewed on November 16, 2026.
Research peptides in Oklahoma: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Of these five, four ship to Oklahoma: BPC-157, TB-500, Epitalon and MOTS-c, all compounded as injectables. KPV does not, because the peptide formulary is injectable-form only. The sections below state each line’s own federal record, and they appear on every state page in identical cited words, whether or not the line is available there.
BPC-157 in Oklahoma
Compounded as an injectable for Oklahoma addresses, dispensed on a patient-specific prescription. The two federal facts below come with it.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Oklahoma
In the Oklahoma offering as a compounded injectable; a patient-specific prescription is required. Federal record below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Oklahoma
We do not carry KPV, in Oklahoma or anywhere. Our peptide formulary is injectable-form only.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Oklahoma
Available for Oklahoma orders as a compounded injectable; the federal record below applies in full.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Oklahoma
Fills to Oklahoma as a compounded injectable. Its federal entry below is distinct from the other four lines’.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Oklahoma’s pharmacy regulators require
Oklahoma’s requirements are procedural rather than medication-specific. The three cited positions below are the ones that matter for an order shipped to an Oklahoma address.
Oklahoma Administrative Code 535:15-3-9 requires a non-resident pharmacy that dispenses or delivers prescription medications to Oklahoma residents to hold an annual non-resident pharmacy license from the Oklahoma State Board of Pharmacy, maintain good standing in its home state, submit a pharmacy inspection conducted within the previous 24 months, and name an Oklahoma-licensed pharmacist-in-charge. Source: Oklahoma State Board of Pharmacy — Pharmacy Law Book (PDF).
Oklahoma regulates pharmacy compounding through the general pharmacy rules of Oklahoma Administrative Code Title 535; the board has published no GLP-1-specific or peptide-specific compounding guidance. Source: Oklahoma State Board of Pharmacy — Pharmacy Law Book (PDF).
Oklahoma recognizes a valid physician-patient relationship established through telemedicine, provided the physician holds an Oklahoma medical license. Source: CCHP Policy Finder — Oklahoma.
For an Oklahoma patient the sequence is unchanged: eligibility check, telemedicine evaluation with an Oklahoma-licensed provider, fulfillment by a pharmacy holding the non-resident credential above: inspected, in good standing at home, with an Oklahoma-licensed pharmacist-in-charge on file. National pricing applies at every dose.
Oklahoma availability FAQs
Is compounded semaglutide available in Oklahoma?
Yes. OrderlyMeds ships compounded semaglutide to Oklahoma addresses under patient-specific prescriptions; new customers start at $74/month for the first two months.
How does an out-of-state pharmacy ship medication to Oklahoma?
By holding Oklahoma's annual non-resident pharmacy license, which takes good standing at home, a recent inspection on file, and an Oklahoma-licensed pharmacist-in-charge. The regulator section above cites the rule.
Can I get BPC-157 or other research peptides shipped to Oklahoma?
Four of the five ship to Oklahoma as compounded injectables under patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not. Each section above states that line's own federal record.
How long does delivery to Oklahoma take?
8–10 business days from signup is the published window.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
